Cited by 314Obsessive-Compulsive Spectrum DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychoanalysis and Psychopathology Research

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial

Coric, Vladimir, Taskiran, Sarper, Pittenger, Christopher, Wasylink, Suzanne, Mathalon, Daniel H., Valentine, Gerald, Saksa, John, Wu, Yu-te, Gueorguieva, Ralitza, Sanacora, Gerard, Malison, Robert T., Krystal, John H.·2005·Biological Psychiatry

DOI 10.1016/j.biopsych.2005.04.043

Open this paper in CoChat — free account

Abstract

Background Most patients with obsessive-compulsive disorder (OCD) show only partial reduction of symptoms with standard therapy. Recent imaging data suggests glutamatergic dysfunction in the corticostriatal pathway in OCD. We investigated the efficacy of augmentation therapy with riluzole, a glutamate-modulating agent, in treatment-resistant OCD.Methods Thirteen patients aged between 18 and 65 years with a primary diagnosis of OCD that had proven resistant to standard treatment were treated with the addition of riluzole to their existing pharmacotherapy. Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Hamilton Depression Inventory (HAM-D), and Hamilton Anxiety Inventory (HAM-A) scores were obtained weekly.Results Thirteen treatment-resistant OCD patients received riluzole 50 mg twice a day. Y-BOCS scores improved significantly over time. Of 13 patients, 7 (54%) demonstrated a >35% reduction in Y-BOCS scores, and 5 (39%) were categorized as treatment responders. HAM-D and HAM-A scores for the group also significantly improved over time. Riluzole was well tolerated with no serious adverse effects noted.Conclusions Riluzole appears to have significant antiobsessional, antidepressant, and antianxiety properties. The addition of this agent may be of practical clinical benefit in patients with OCD.

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2005.04.043

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Applied Mixed Models in Medicine
Brown, H., & Presco, R. (2000) · Technometrics · doi:10.1080/00401706.2000.10485742 · Cited by 1,699
Move Over ANOVA: Progress in Analyzing Repeated-Measures Data andIts Reflection in Papers Published in the Archives of General Psychiatry
Gueorguieva, R., & Krystal, J. H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.3.310 · Cited by 1,529
Energy on demand.
Magistretti, P. J., Pellerin, L., Rothman, D. L., & Shulman, R. G. (1999) · Science · doi:10.1126/science.283.5401.496 · Cited by 1,170
Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression
Sanacora, G., Gueorguieva, R. V., Epperson, C. N., Wu, Y., Appel, M., Rothman, D. L., Krystal, J. H., & Mason, G. F. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.705 · Cited by 796
Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study
Auer, D. P., Pütz, B., Kraft, E., Lipinski, B., Schill, J., & Holsboer, F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00159-6 · Cited by 562
Neurobiology of Mental Illness
(2011) · Oxford University Press eBooks · doi:10.1093/med/9780199798261.001.0001 · Cited by 523
Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13 C NMR
Shen, J., Petersen, K. F., Behar, K. L., Brown, P., Nixon, T. W., Mason, G. F., Petroff, O. A. C., Shulman, G. I., Shulman, R. G., & Rothman, D. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8235 · Cited by 462
The Physicians' Desk Reference
Cohen, J. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440120021003 · Cited by 430
Riluzole inhibits the persistent sodium current in mammalian CNS neurons
Urbani, A., & Belluzzi, O. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00242.x · Cited by 381
Decrease in Caudate Glutamatergic Concentrations in Pediatric Obsessive-Compulsive Disorder Patients Taking Paroxetine
ROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377

Flagged first, then by citations

Show all 25 references

Sorted by citations

Items 101–200 of 313

Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H., & DeLorenzo, C. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.025 · Cited by 50
Self-citation
Pharmacotherapeutic Strategies and New Targets in OCD
Pittenger, C. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_204 · Cited by 54
Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report
Uzun, Ö. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108098809 · Cited by 49
Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach
Grados, M. A., Specht, M. W., Sung, H.-M., & Fortune, D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.845553 · Cited by 49
Pharmacotherapies in the Management of Obsessive—Compulsive Disorder
Blier, P., Habib, R., & Flament, M. F. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100703 · Cited by 50
A screen of SLC1A1 for OCD‐related alleles
Wang, Y., Adamczyk, A., Shugart, Y. Y., Samuels, J. F., Grados, M. A., Greenberg, B. D., Knowles, J. A., McCracken, J. T., Rauch, S. L., Murphy, D. L., et al. (2010) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31001 · Cited by 47
A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia
Farokhnia, M., Sabzabadi, M., Pourmahmoud, H., Khodaie-Ardakani, M.-R., Hosseini, S.-M.-R., Yekehtaz, H., Tabrizi, M. H., Rezaei, F., Salehi, B., & Akhondzadeh, S. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3261-z · Cited by 47
Beneficial Effects of the Glutamate-modulating Agent Riluzole on Disordered Eating and Pathological Skin-picking Behaviors
Sasso, D. A., Kalanithi, P. S. A., Trueblood, K. V., Pittenger, C., Kelmendi, B., Wayslink, S., Malison, R. T., Krystal, J. H., & Coric, V. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000245567.29531.d6 · Cited by 47
Glutamate System Genes Associated with Ventral Prefrontal and Thalamic Volume in Pediatric Obsessive-Compulsive Disorder
Arnold, P. D., MacMaster, F. P., Hanna, G. L., Richter, M. A., Sicard, T., Burroughs, E., Mirza, Y., Easter, P. C., Rose, M., Kennedy, J. L., et al. (2009) · Brain Imaging and Behavior · doi:10.1007/s11682-008-9050-3 · Cited by 46
Advances in pharmacotherapy for pediatric anxiety disorders
Rynn, M. A., Puliafico, A. C., Heleniak, C. M., Rikhi, P., Ghalib, K., & Vidair, H. B. (2011) · Depression and Anxiety · doi:10.1002/da.20769 · Cited by 45
The role of NMDA receptors in the signal attenuation rat model of obsessive–compulsive disorder
Albelda, N. S., Bar-On, N., & Joel, D. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1808-9 · Cited by 43
An update on the pharmacological treatment of obsessive-compulsive disorder
Fontenelle, L. F., Nascimento, A. L., Mendlowicz, M. V., Shavitt, R. G., & Versiani, M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.5.563 · Cited by 41
Initial Evidence of the Beneficial Effects of Glutamate-Modulating Agents in the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder
Pittenger, C., Krystal, J. H., & Coric, V. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1121d · Cited by 42
The Neurochemistry of Tourette Syndrome
Singer, H. S. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796267.003.0013 · Cited by 41
Glutamate, obsessive–compulsive disorder, schizophrenia, and the stability of cortical attractor neuronal networks
Rolls, E. T. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.017 · Cited by 39
Sarcosine Therapy for Obsessive Compulsive Disorder
Wu, P.-L., Tang, H., Lane, H., Tsai, C., & Tsai, G. E. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182189878 · Cited by 40
Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression
Delgado-Acevedo, C., Estay, S. F., Radke, A. K., Sengupta, A., Escobar, A. P., Henríquez-Belmar, F., Reyes, C. A., Haro‐Acuña, V., Utreras, E., Sotomayor‐Zárate, R., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0302-7 · Cited by 42
Isoforms of the neuronal glutamate transporter gene, SLC1A1/EAAC1, negatively modulate glutamate uptake: relevance to obsessive-compulsive disorder
Porton, B., Greenberg, B. D., Askland, K., Serra, L. M., Gesmonde, J., Rudnick, G., Rasmussen, S. A., & Kao, H.-T. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.35 · Cited by 36
A selective review of glutamate pharmacological therapy in obsessive–compulsive and related disorders
Grados, M. A., Atkins, E., Kovacikova, G. I., & McVicar, E. L. (2015) · Psychology Research and Behavior Management · doi:10.2147/prbm.s58601 · Cited by 41
Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial.
Afshar, H., Akuchekian, S., Mahaky, B., & Zarean, E. (2014) · Europe PMC (PubMed Central) · Cited by 39
Treatment-refractory obsessive compulsive disorder
Atmaca, M. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.12.004 · Cited by 38
Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder
Sahraian, A., Jahromi, L. R., Ghanizadeh, A. J., & Mowla, A. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000651 · Cited by 39
Glutamatergic Dysfunction-Newer Targets for Anti-Obsessional Drugs
Bhattacharyya, S., & Chakraborty, K. (2007) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488907779561727 · Cited by 40
Predicting Changes in Obsessive Compulsive Symptoms Over a Six-Month Follow-Up: A Prospective Test of Cognitive Models of Obsessive Compulsive Disorder
Coles, M. E., Pietrefesa, A. S., Schofield, C. A., & Cook, L. M. (2007) · Cognitive Therapy and Research · doi:10.1007/s10608-007-9132-3 · Cited by 41
Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines
Sugiyama, A., Saitoh, A., Iwai, T., Takahashi, K., Yamada, M., Sasaki-Hamada, S., Oka, J.-I., Inagaki, M., & Yamada, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.02.012 · Cited by 38
Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?
Önder, E., Tural, Ü., & Gökbakan, M. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0798-z · Cited by 38
Glutamate Modulators in the Treatment of Obsessive-Compulsive Disorder
Pittenger, C. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150602-06 · Cited by 41
Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
Khalkhali, M., Aram, S., Zarrabi, H., Kafie, M., & Heidarzadeh, A. (2016) · PubMed Central · Cited by 36
Nondopaminergic Neurotransmission in the Pathophysiology of Tourette Syndrome
Udvardi, P. T., Nespoli, E., Rizzo, F. R., Hengerer, B., & Ludolph, A. G. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00004-4 · Cited by 37
A call for prevention and early intervention in obsessive‐compulsive disorder
Brakoulias, V., Perkes, I. E., & Tsalamanios, E. (2017) · Early Intervention in Psychiatry · doi:10.1111/eip.12535 · Cited by 35
Treatment strategies for obsessive-compulsive disorder
Marazziti, D., & Consoli, G. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903446948 · Cited by 37
L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study
Arabzadeh, S., Shahhossenie, M., Mesgarpour, B., Rezaei, F., Shalbafan, M., Ghiasi, Z., & Akhondzadeh, S. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2584 · Cited by 36
Diagnosis and Treatment of a Patient With Both Psychotic and Obsessive-Compulsive Symptoms
Rodríguez, C. I., Corcoran, C. M., & Simpson, H. B. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09070997 · Cited by 32
Silver-Catalyzed Dibromotrifluoromethoxylation of Terminal Alkynes
Wang, F. Y., Guo, Y., Zhang, Y., & Tang, P. (2021) · ACS Catalysis · doi:10.1021/acscatal.1c00090 · Cited by 32
An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder
Chaudhury, S., Bakhla, A. K., Verma, V. K., Soren, S., & Sarkhel, S. (2013) · Industrial Psychiatry Journal · doi:10.4103/0972-6748.132930 · Cited by 32
A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder
Wink, L. K., Adams, R. E., Horn, P. S., Tessier, C. R., Bantel, A. P., Hong, M. P., Shaffer, R. C., Pedapati, E. V., & Erickson, C. A. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3562-5 · Cited by 30
Beneficial Effects of the Antiglutamatergic Agent Riluzole in a Patient Diagnosed With Trichotillomania
Coric, V., Kelmendi, B., Pittenger, C., Wasylink, S., Bloch, M. H., & Green, J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0123f · Cited by 29
Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) – study protocol for a randomised controlled trial
Häge, A., Banaschewski, T., Buitelaar, J. K., Dijkhuizen, R. M., Franke, B., Lythgoe, D. J., Mechler, K., Williams, S., & Dittmann, R. (2016) · Trials · doi:10.1186/s13063-016-1266-8 · Cited by 32
Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: A randomized placebo-controlled clinical trial
Sayyah, M., Olapour, A., Saeedabad, Y. S., Yazdan Parast, R., & Malayeri, A. (2012) · Nutrition · doi:10.1016/j.nut.2011.11.027 · Cited by 28
Treatment of obsessive-compulsive disorders (OCD) and obsessive-compulsive-related disorders (OCRD)
Krzyszkowiak, W., Kuleta-Krzyszkowiak, M., & Krzanowska, E. (2019) · Psychiatria Polska · doi:10.12740/pp/105130 · Cited by 28
Effects of agents targeting glutamatergic systems on marble-burying behavior
Iijima, M., Kurosu, S., & Chaki, S. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.12.048 · Cited by 28
High-Dose Glycine Treatment of Refractory Obsessive-Compulsive Disorder and Body Dysmorphic Disorder in a 5-Year Period
Cleveland, W. L., DeLaPaz, R. L., Fawwaz, R. A., & Challop, R. S. (2009) · Neural Plasticity · doi:10.1155/2009/768398 · Cited by 30
Neurobiology of maternal mental illness
Maguire, J., McCormack, C., Mitchell, A., & Monk, C. E. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64239-4.00005-9 · Cited by 28
The Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.11.005 · Cited by 26
Riluzole in Autistic Disorder
Wink, L. K., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0154 · Cited by 26
Effects of mood stabilizers on marble-burying behavior in mice
Egashira, N., Abe, M., Shirakawa, A., Niki, T., Mishima, K., Iwasaki, K., Oishi, R., & Fujiwara, M. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2904-9 · Cited by 26
Chapter 4.4 The glutamatergic system as a potential therapeutic target for the treatment of anxiety disorders
Cryan, J. F., & Dev, K. K. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(07)00013-6 · Cited by 25
Emerging drugs to treat obsessive–compulsive disorder
Pallanti, S., Grassi, G., & Cantisani, A. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.875157 · Cited by 23
Association Between SLC1A1 Gene and Early-Onset OCD in the Han Chinese Population: A Case–Control Study
Wu, H., Wang, X., Xiao, Z., Yu, S., Zhu, L., Wang, D., Jiang, K., Wang, Z., Zhang, T., & Fralick, D. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-9995-6 · Cited by 24
Glutamatergic augmentation strategies in obsessive–compulsive disorder
Narayanaswamy, J., & Sheshachala, K. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_520_18 · Cited by 24
Treating OCD: what to do when first-line therapies fail
Castle, D. J., Bosanac, P., & Rossell, S. L. (2015) · Australasian Psychiatry · doi:10.1177/1039856215590027 · Cited by 23
Clozapine-Induced Pericarditis, Pericardial Tamponade, Polyserositis, and Rash
Bhatti, M. A., Zander, J., & Reeve, E. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1121a · Cited by 23
Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder
Pittenger, C., Brennan, B. P., Koran, L. M., Mathews, C. A., Nestadt, G., Pato, M. T., Phillips, K. A., Rodríguez, C. I., Simpson, H. B., Skapinakis, P., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113853 · Cited by 22
Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive–compulsive symptoms induced by second-generation antipsychotic agents
Schirmbeck, F. N., Nieratschker, V., Frank, J., Englisch, S., Rausch, F., Meyer‐Lindenberg, A., Rietschel, M., & Zink, M. (2012) · Psychiatric Genetics · doi:10.1097/ypg.0b013e328353fbee · Cited by 22
Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature
Mechler, K., Häge, A., Schweinfurth, N., Glennon, J. C., Dijkhuizen, R. M., Murphy, D., Durston, S., Williams, S., Buitelaar, J. K., Banaschewski, T., et al. (2017) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000546 · Cited by 22
The Neuronal Glutamate Transporter EAAT3 in Obsessive-Compulsive Disorder
Escobar, A. P., Wendland, J. R., Chávez, A. E., & Moya, P. R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01362 · Cited by 22
Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive–compulsive disorder
Real, E., Gratacòs, M., Labad, J., Alonso, P., Escaramís, G., Segalàs, C., Subirà, M., López‐Solà, C., Estivill, X., & Menchón, J. M. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.30 · Cited by 21
N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series
Ameringen, M. V., Patterson, B. A., Simpson, W. S., & Turna, J. (2012) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2012.10.003 · Cited by 24
Riluzole and d-amphetamine interactions in humans
Sofuoglu, M., Waters, A. J., Mooney, M. E., & Kosten, T. R. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.05.003 · Cited by 21
Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder
Sharafkhah, M., Alamdar, M. A., Massoudifar, A., Abdolrazaghnejad, A., Ebrahimi-Monfared, M., Saber, R., & Mohammadbeigi, A. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000267 · Cited by 21
Obsessive-Compulsive Disorder: Diagnosis, Epidemiology, Etiology, and Treatment
Sassano-Higgins, S. A., & Pato, M. T. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130211 · Cited by 19
Glutamate-based anxiolytic ligands in clinical trials
Wierońska, J. M., & Pilc, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.803066 · Cited by 20
The Genetics of Obsessive-Compulsive Disorder
Stewart, S. E., & Pauls, D. L. (2010) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.8.3.foc350 · Cited by 22
An Association of Intrusive, Repetitive Phrases with Lamotrigine Treatment in Bipolar II Disorder
Kemp, D. E., Gilmer, W. S., Fleck, J., & Dago, P. L. (2007) · CNS Spectrums · doi:10.1017/s1092852900020617 · Cited by 20
Riluzole in the prelimbic medial prefrontal cortex attenuates veratrine-induced anxiety-like behaviors in mice
Ohashi, M., Saitoh, A., Yamada, M., Oka, J.-I., & Yamada, M. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3676-1 · Cited by 19
The Glutamate and the Immune Systems: New Targets for the Pharmacological Treatment of OCD
Marazziti, D., Albert, U., Mucci, F., & Piccinni, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666171108152035 · Cited by 19
Translational neuroimaging research in pediatric obsessive-compulsive disorder
Master, F. P. M. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.2/fmacmaster · Cited by 19
Management of obsessive-compulsive disorder comorbid with bipolar disorder
Kazhungil, F., & Mohandas, E. (2016) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.192001 · Cited by 17
Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder
Spangler, P. T., West, J. C., Dempsey, C. L., Possemato, K., Bartolanzo, D., Aliaga, P. A., Zarate, C. A., Vythilingam, M., & Benedek, D. M. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13233 · Cited by 18
Combination therapy with neuropeptides for the treatment of anxiety disorder
Gupta, P. R., & Prabhavalkar, K. S. (2021) · Neuropeptides · doi:10.1016/j.npep.2021.102127 · Cited by 17
Potential role of anticonvulsants in the treatment of obsessive–compulsive and related disorders
Wang, H. R., Woo, Y. S., & Bahk, W. (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12186 · Cited by 16
Involvement of NMDA receptor complex in the anxiolytic-like effects of chlordiazepoxide in mice
Poleszak, E., Socała, K., Szopa, A., Wróbel, A., Szewczyk, B., Kasperek, R., Blicharska, E., Nowak, G., & Właź, P. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0585-x · Cited by 18
A review of N‐acetylcysteine in the treatment of grooming disorders
Braun, T. L., Patel, V., DeBord, L., & Rosen, T. (2019) · International Journal of Dermatology · doi:10.1111/ijd.14371 · Cited by 18
A primary candidate gene for obsessive-compulsive disorder.
Leckman, J., & Kim, Y.-S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.717 · Cited by 14
Advances in the management of treatment-resistant anxiety disorders
Lanouette, N. M., & Stein, M. B. (2010) · Focus · doi:10.1176/foc.8.4.foc501 · Cited by 15
Neuromodulation in Psychiatry
Sharma, M., Zibly, Z., Deogaonkar, M. S., & Rezai, A. R. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_38 · Cited by 16
Effect of the Metabotropic Glutamate Receptor Type 5 Negative Allosteric Modulator Dipraglurant on Motor and Non-Motor Symptoms of Parkinson’s Disease
Epping-Jordan, M. P., Girard, F., Bessis, A., Mutel, V., Boléa, C., Derouet, F., Bessif, A., Mingard, B., Barbier, S., Paradis, J. S., et al. (2023) · Cells · doi:10.3390/cells12071004 · Cited by 14
The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia
Vellucci, L., Ciccarelli, M., Buonaguro, E. F., Fornaro, M., D’Urso, G., Simone, G. D., Iasevoli, F., Barone, A., & de Bartolomeis, A. (2023) · Biomolecules · doi:10.3390/biom13081220 · Cited by 16
Pharmacotherapy for obsessive—compulsive disorder
Fineberg, N. A., & Brown, A. (2011) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.109.007237 · Cited by 15
Psychotherapy and medication management strategies for obsessive-compulsive disorder
Walsh, K. H., & McDougle (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s13205 · Cited by 15
[Comorbidity between obsessive-compulsive disorder and schizophrenia: prevalence, explanatory theories, and nosological status].
Frías, Á., Palma, C., & Farriols, N. (2014) · Actas Españolas de Psiquiatría · Cited by 14
Addressing the Complexity of Tourette's Syndrome through the Use of Animal Models
Nespoli, E., Rizzo, F. R., Boeckers, T. M., Hengerer, B., & Ludolph, A. G. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00133 · Cited by 16
Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal 1H-NMR spectroscopy study at 11.7T
Rizzo, F. R., Abaei, A., Nespoli, E., Fegert, J. M., Hengerer, B., Rasche, V., & Boeckers, T. M. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.167 · Cited by 14
Obsessive–Compulsive Disorder
Koen, N., & Stein, D. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00038-0 · Cited by 13
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders
Katzman, M. A., Bleau, P., Blier, P., Chokka, P. R., Kjernisted, K. D., & Ameringen, M. V. (2021) · doi:10.32920/14638581 · Cited by 13
Ketogenic Diet as a Nutritional Metabolic Intervention for Obsessive–Compulsive Disorder: A Narrative Review
Lounici, A., Iacob, A., Hongler, K., Mölling, M. A., Drechsler, M., Hersberger, L., Sethi, S., Lang, U. E., & Liwinski, T. (2024) · Nutrients · doi:10.3390/nu17010031 · Cited by 14
Glutamatergic dysfunction in obsessive-compulsive disorder and the potential clinical utility of glutamate-modulating agents
Pittenger, C., Bloch, M. H., Wegner, R., Teitelbaum, C., Krystal, J. H., & Coric, V. (2006) · Primary psychiatry · Cited by 12
Amantadine Augmentation for Refractory Obsessive-Compulsive Disorder
Pasquini, M., Berardelli, I., & Biondi, M. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c8b44f · Cited by 11
Role of Lamotrigine Augmentation in Treatment-Resistant Obsessive Compulsive Disorder: A Retrospective Case Review from South Asia
Hussain, A., Dar, M. A., Wani, R. A., Shah, M. S., Jan, M. M., Malik, Y. A., Chandel, R. K., & Margoob, M. A. (2015) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.155613 · Cited by 11
Tourette Syndrome and Tic Disorders
Tochen, L. S., & Singer, H. S. (2016) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-802206-1.00048-9 · Cited by 11
Obsessive–Compulsive Disorder
Murphy, T. K., Frazier, S., & Kim, S. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-252-6_10 · Cited by 11
Emerging role of glutamate in the pathophysiology and therapeutics of Gulf War illness
Wang, X., Ali, N., & Lin, C. G. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119609 · Cited by 12
Tiagabine augmentation to fluvoxamine–risperidone combination in the treatment of obsessive-compulsive disorder
Oulis, P., Masdrakis, V. G., Karapoulios, E., Karakatsanis, N. A., Kouzoupis, A. V., Konstantakopoulos, G., & Soldatos, C. R. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701739526 · Cited by 11
Experimental therapeutics for refractory obsessive‐compulsive disorder: translational approaches and new somatic developments
Berlin, H. A., Hamilton, H., & Hollander, E. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20045 · Cited by 10
Lamotrigine Augmentation in Treatment-Resistant Pediatric Obsessive-Compulsive Disorder with a 16 Month Follow-up
Naguy, A., Alamiri, B., AlKhadhari, S., & Francis, K. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0083 · Cited by 10
Biological treatments for obsessive-compulsive and related disorders
Borue, X., Sharma, M., & Hudak, R. (2015) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2015.03.003 · Cited by 11
Obsessive-Compulsive Disorder: An Update for the Clinician
Koran, L. M. (2007) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.5.3.foc299 · Cited by 11
Enantioselective Benzylation and Allylation of α-Trifluoromethoxy Indanones under Phase-Transfer Catalysis
Liang, Y., Maeno, M., Zhao, Z., & Shibata, N. (2019) · Molecules · doi:10.3390/molecules24152774 · Cited by 10
Neurobiology Confirms Psychopathology
Zink, M., Englisch, S., & Dreßing, H. R. (2008) · Psychopathology · doi:10.1159/000141922 · Cited by 10
Increase in Valproic Acid Levels During Riluzole Treatment in an Adolescent with Autism
Veenstra-VanderWeele, J. M. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0087 · Cited by 10

Authors: Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., Malison, R. T., & Krystal, J. H.
Affiliations: Yale University (US)
ORCID: Taskiran, Sarper
Pittenger, Christopher
Mathalon, Daniel H.
Valentine, Gerald
Wu, Yu-te
Gueorguieva, Ralitza
Sanacora, Gerard
Malison, Robert T.
Krystal, John H.
Venue: Biological Psychiatry
Publisher: Elsevier BV
Published: 2005-09
Volume: 58
Issue: 5
Pages: 424-428
ISSN: 0006-3223 (ISSN-L)
DOI: 10.1016/j.biopsych.2005.04.043
OpenAlex: W1982538263
Cited by: 314
References: 25
Citations by year: 2026: 7 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 10 · 2020: 8 · 2019: 12 · 2018: 5 · 2017: 15 · 2016: 15 · 2015: 21 · 2014: 21 · 2013: 22 · 2012: 23
FWCI: 25.07
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5k05aa014906-03)
National Institute on Alcohol Abuse and Alcoholism (K05 AA 14906-01)
National Center for Research Resources (M01RR000125, M01 RR-00125)
Topics: Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords: riluzole, treatment-resistant OCD, augmentation therapy, glutamate modulation, glutamatergic dysfunction, corticostriatal pathway, antidepressant effects, anxiolytic effects, adverse effects
MeSH terms: Adult, Drug Resistance, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Time Factors, Treatment Outcome, Excitatory Amino Acid Antagonists, Riluzole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks